Management of cancer-related anemia in patients with breast or gynecologic cancer
Standard
Management of cancer-related anemia in patients with breast or gynecologic cancer : new insights based on results from the European Cancer Anemia Survey. / Barrett-Lee, Peter; Bokemeyer, Carsten; Gascón, Pere; Nortier, J W R; Schneider, Maurice; Schrijvers, Dirk; Van Belle, Simon; ECAS Advisory Board and Participating Centers.
in: ONCOLOGIST, Jahrgang 10, Nr. 9, 10.2005, S. 743-57.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Management of cancer-related anemia in patients with breast or gynecologic cancer
T2 - new insights based on results from the European Cancer Anemia Survey
AU - Barrett-Lee, Peter
AU - Bokemeyer, Carsten
AU - Gascón, Pere
AU - Nortier, J W R
AU - Schneider, Maurice
AU - Schrijvers, Dirk
AU - Van Belle, Simon
AU - ECAS Advisory Board and Participating Centers
PY - 2005/10
Y1 - 2005/10
N2 - The incidence, prevalence, and treatment of anemia (hemoglobin [Hb] <12 g/dl) in women with breast cancer and gynecologic cancer were evaluated using data from the European Cancer Anemia Survey (ECAS). Adult patients with newly diagnosed treated or untreated disease, persistent/recurrent disease, and disease in remission were enrolled and followed for up to six chemotherapy cycles or six evaluation points within a 6-month period. At enrollment, 30.4% of breast cancer patients and 49.1% of gynecologic cancer patients were anemic. A significant correlation was shown between low Hb level and poor performance status (World Health Organization criteria) at enrollment for both breast cancer and gynecologic cancer patients. In all, 62.4% of breast cancer patients and 81.4% of gynecologic cancer patients were anemic at some time during the survey. The incidence of anemia, determined in a carefully defined population, was 59.8% for breast cancer patients and 74.8% for gynecologic cancer patients. Despite the high prevalence and incidence of anemia, only 26.3% and 42.7% of patients in the respective groups received anemia treatment. In breast cancer patients, the mean Hb trigger was 10 g/dl for epoetin treatment and 8.6 g/dl for transfusion; corresponding values for gynecologic cancer patients were 10.1 g/dl and 9.1 g/dl. Logistic regression analyses in the overall ECAS population identified five factors as significant and suitable predictors of anemia: lower initial Hb, having lung or gynecologic cancer versus gastrointestinal/colorectal cancer, any other cancer versus gastrointestinal/colorectal cancer, treatment with platinum chemotherapy, and being female. The ECAS data highlight the need for greater awareness of the adverse impact of anemia on cancer patients and for optimal anemia management to ensure maximal patient quality of life.
AB - The incidence, prevalence, and treatment of anemia (hemoglobin [Hb] <12 g/dl) in women with breast cancer and gynecologic cancer were evaluated using data from the European Cancer Anemia Survey (ECAS). Adult patients with newly diagnosed treated or untreated disease, persistent/recurrent disease, and disease in remission were enrolled and followed for up to six chemotherapy cycles or six evaluation points within a 6-month period. At enrollment, 30.4% of breast cancer patients and 49.1% of gynecologic cancer patients were anemic. A significant correlation was shown between low Hb level and poor performance status (World Health Organization criteria) at enrollment for both breast cancer and gynecologic cancer patients. In all, 62.4% of breast cancer patients and 81.4% of gynecologic cancer patients were anemic at some time during the survey. The incidence of anemia, determined in a carefully defined population, was 59.8% for breast cancer patients and 74.8% for gynecologic cancer patients. Despite the high prevalence and incidence of anemia, only 26.3% and 42.7% of patients in the respective groups received anemia treatment. In breast cancer patients, the mean Hb trigger was 10 g/dl for epoetin treatment and 8.6 g/dl for transfusion; corresponding values for gynecologic cancer patients were 10.1 g/dl and 9.1 g/dl. Logistic regression analyses in the overall ECAS population identified five factors as significant and suitable predictors of anemia: lower initial Hb, having lung or gynecologic cancer versus gastrointestinal/colorectal cancer, any other cancer versus gastrointestinal/colorectal cancer, treatment with platinum chemotherapy, and being female. The ECAS data highlight the need for greater awareness of the adverse impact of anemia on cancer patients and for optimal anemia management to ensure maximal patient quality of life.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Anemia
KW - Breast Neoplasms
KW - Female
KW - Genital Neoplasms, Female
KW - Hemoglobins
KW - Humans
KW - Incidence
KW - Middle Aged
KW - Prevalence
KW - Prospective Studies
KW - Risk Factors
U2 - 10.1634/theoncologist.10-9-743
DO - 10.1634/theoncologist.10-9-743
M3 - SCORING: Journal article
C2 - 16249356
VL - 10
SP - 743
EP - 757
JO - ONCOLOGIST
JF - ONCOLOGIST
SN - 1083-7159
IS - 9
ER -